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Pyoderma gangrenosum (PG) is an uncommon
ulcerative cutaneous condition, the etiology of
which is poorly understood but is thought to be
related to improper neutrophil function and
chemotaxis. PG is a clinical diagnosis that requires
exclusion of other ulcerative and inflammatory
cutaneous disorders. A rare side effect of isotretinoin
is the development of PG. We report the first case, to
our knowledge, of PG associated with alitretinoin
therapy (Appendix).CASE REPORT
A 45-year-old womanwith a long-standing history
of presumed bilateral hand and foot eczema was
treated with alitretinoin after not responding to
topical super potent corticosteroid therapy. She
was started on alitretinoin (30 mg daily), and
the dermatitis significantly improved. However,
5 months after initiation of therapy, a painful ulcer
developed on her left shin. Treatment with multiple
courses of intravenous antibiotics was not effective.
The patient was then referred to our dermatology
clinic while still taking alitretinoin.
Physical examination found 2 discrete ulcers with
violaceous, undermined borders on her left lower
leg (Fig 1). The histopathologic features seen in the
punch biopsy section taken from the left shin were
mild and nonspecific (Figs 2 and 3). The epidermis
was mildly acanthotic with the area of ulceration
missing in the sampling. Mildly increased vascularity
was noted in the papillary dermis, suggesting
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3. E-mail: Alain.brassard@ualberta.ca.neutrophilic infiltrate, granulomatous inflammation,
and vasculitis were not noted. Periodic acideSchiff
stain was negative for fungal elements. Sterile
superficial and deep skin cultures were negative
for bacteria, fungi, and mycobacteria. Other
investigations including complete blood count,
serum protein electrophoresis, liver enzymes, and
urinalysis were within normal limits, and hepatitis B
surface antigen, antibody to hepatitis C, and HIV
results were negative. Her medical history is relevant
for eczema, type 2 diabetes mellitus, gastroesopha-
geal reflux disease, and hypercholesterolemia. The
patient had no systemic symptoms, including
arthralgias or gastrointestinal symptoms, and did
not suffer from any of the conditions noted to be
associated with PG. PGwas clinically diagnosed, and
alitretinoin was withdrawn, as it was suspected to be
the cause of the PG. The patient was treated
with tacrolimus, 0.1% ointment twice daily, and
intralesional corticosteroids. The ulcers did not heal
completely, but after treatment with prednisone,
20 mg orally once daily, the ulcers healed within
2 months with cribriform scarring.
At the patient’s request, and informed consent of
an understanding of the risks, she was restarted on
alitretinoin because of worsening hand dermatitis. A
painful nodule developed at the same site on the leg
5 weeks after reinitiation. After prompt discontinu-
ation, the lesions resolved in 3 weeks and neverJAAD Case Reports 2016;2:135-7.
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Fig 1. Pyoderma gangrenosum of the left lower extremity.
Two necrolytic cutaneous ulcers with irregular, viola-
ceous, and undermined borders. Cribriform scarring is
present at sites treated with intralesional corticosteroids.
Fig 2. Pyoderma gangrenosum. Low-power examination
shows mild nonspecific changes. Ulceration is not seen in
this biopsy. (Hematoxylin-eosin stain; original magnifica-
tion: 325.)
Fig 3. Pyoderma gangrenosum. High-power examination
shows mildly increased vascularity in the papillary dermis.
Dense neutrophilic infiltrate is not seen. (Hematoxylin-
eosin stain; original magnification: 3100.)
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was consistent with psoriasis. Given the new
diagnosis, the patient was then treated with
narrow-band ultraviolet B phototherapy with a
moderate response. She later started ustekinumab
(45 mg subcutaneously at weeks 0 and 4 and then
every 12 weeks) and her hands cleared. After the PG,
she did not have inflammatory bowel disease,
arthritis, or any hematologic disorder.DISCUSSION
PG is an uncommon neutrophilic dermatosis that
presents as an inflammatory and ulcerative disorderof the skin. To our knowledge, this is the first
reported case of PG in association with treatment
with alitretinoin. Five cases of PG associated with
isotretinoin therapy have been reported,1-5 but PG
associated with alitretinoin or any of the other
retinoids has never been reported. The mechanism
of PG resulting from retinoid use is unknown, but it is
suggested that it is related to altered neutrophil
chemotaxis,5 increased skin fragility, or vascular
proliferation.1,6
The biopsy result in this case showed nonspecific
changes, and features diagnostic for PG were not
seen. Two possibilities may account for this: the
biopsy was taken from an area peripheral to the
lesion, thus, missing the main findings or the lesion
was partially treated or resolved at the time of
biopsy, and only chronic nonspecific histopatholo-
gic changes remained. The location of the ulcers,
presence of pain, undermining and cribriform
scarring, negative tissue cultures, and rapid response
to systemic steroid therapy are in keeping with a
diagnosis of PG despite the lack of confirmatory
histologic findings, which are not required for
diagnosis.7
PG is associated with several autoinflammatory
syndromes, but given our patient’s lack of acne,
hidradenitis suppurativa, arthritis, and systemic
symptoms, her findings are not consistent with
pyogenic arthritis, PG, and acne (PAPA) syndrome;
PG, acne, and suppurative hidradenitis (PASH)
syndrome8; or pyogenic arthritis, PG, acne, and
hidradenitis suppurativa syndrome.9 Other autoin-
flammatory conditions, such as deficiency of the
interleukin-1 receptor antagonist; deficiency of the
interleukin-36 receptor antagonist; and synovitis,
acne, pustulosis, hyperostosis, osteitis syndrome,
may present with palmoplantar pustulosis8 but also
have osteoarticular and other findings that are
notably absent in this case.
JAAD CASE REPORTS
VOLUME 2, NUMBER 2
Levy et al 137A small case series that showed the effectiveness
of alitretinoin in treating palmoplantar psoriasis
indicated that alitretinoin altered the number of
innate inflammatory cells, including neutrophils, in
skin sections.10 Paradoxically, isotretinoin was
reported to be efficacious in the treatment of PG in
2 cases11,12 and in the treatment of PAPA syndrome in
a third case.13 Isotretinoin’s paradoxical benefit in
the treatment of PG is postulated to be owing to its
inhibitory effects on neutrophil function.11 Clinicians
should consider the possibility of alitretinoin as the
etiologic factor of PG.
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We state in the manuscript that this is the first
reported case of pyoderma gangrenosum associated
with treatment with alitretinoin. Using the search
criteria pyoderma gangrenosum AND alitretinoin
OR Toctino, we searched both Ovid MEDLINE(R)
and PubMed. The Ovid MEDLINE(R) database was
queried from 1946 to the present, with no limitations
on the published language. This search yielded zero
articles. The PubMed database was queried using the
same search criteria, and the results yielded just
1 article (Scheinfeld N. Dissecting cellulitis
(Perifolliculitis Capitis Abscedens et Suffodiens): a
comprehensive review focusing on new treatments
and findings of the last decade with commentary
comparing the therapies and causes of dissecting
cellulitis to hidradenitis suppurativa. Dermatol
Online J. 2014;20(5):22692); however, this article is
not relevant to the case we are reporting. The
Toctino drug monograph states the following
dermatologic side effects:
1. Common side effects: dryness of the skin,
especially of the lips and face, inflamed skin,
hair loss.
2. Uncommon side effects: hair loss, skin peeling,
rash, dry skin eczema.
There are no rare dermatologic side effects listed.
Ulcers, and specifically pyoderma gangrenosum, are
not listed as one of the side effects of the medication.
Given this review of the literature and product
monograph, we can confidently state that there are
no previous reported cases of our findings in the
published literature.
